100 related articles for article (PubMed ID: 6574535)
61. Behavioral and neuroendocrine effects of low dose ET-495: antagonism by haloperidol.
Angrist B; Ain M; Rotrosen J; Gershon S; Halpern FS; Sachar EJ
J Neural Transm; 1979; 44(4):249-62. PubMed ID: 458429
[TBL] [Abstract][Full Text] [Related]
62. Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics.
Huttunen MO; Tuhkanen H; Haavisto E; Nyholm R; Pitkänen M; Raitasuo V; Romanov M
Psychiatr Serv; 1996 Jan; 47(1):83-5. PubMed ID: 8925352
[TBL] [Abstract][Full Text] [Related]
63. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
Chouinard G
J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
[TBL] [Abstract][Full Text] [Related]
64. Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.
Newman CB; Hurley AM; Kleinberg DL
Clin Endocrinol (Oxf); 1989 Oct; 31(4):391-400. PubMed ID: 2576397
[TBL] [Abstract][Full Text] [Related]
65. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia.
Yuan HN; Wang CY; Sze CW; Tong Y; Tan QR; Feng XJ; Liu RM; Zhang JZ; Zhang YB; Zhang ZJ
J Clin Psychopharmacol; 2008 Jun; 28(3):264-370. PubMed ID: 18480682
[TBL] [Abstract][Full Text] [Related]
66. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
[TBL] [Abstract][Full Text] [Related]
67. Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
Kirkpatrick B; Buchanan RW; Maeda K; Carpenter WT; Jauch D; Tamminga CA
Biol Psychiatry; 1989 Jun; 26(2):131-8. PubMed ID: 2567610
[TBL] [Abstract][Full Text] [Related]
68. Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients.
Otani K; Kondo T; Kaneko S; Ishida M; Fukushima Y
Int Clin Psychopharmacol; 1994; 9(4):287-9. PubMed ID: 7868851
[TBL] [Abstract][Full Text] [Related]
69. Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
Kuhs H; Folkerts H
Neuropsychobiology; 1995; 31(3):135-45. PubMed ID: 7609862
[TBL] [Abstract][Full Text] [Related]
70. Dopamine receptor sensitivity in the hypothalamus of chronic schizophrenics after haloperidol therapy: growth hormone and prolactin response to stimuli.
Brambilla F; Bellodi L; Negri F; Smeraldi E; Malagoli G
Psychoneuroendocrinology; 1979 Oct; 4(4):329-39. PubMed ID: 523590
[No Abstract] [Full Text] [Related]
71. Adenohypophysial dopamine content and prolactin secretion in the aged male and female rat.
Demarest KT; Moore KE; Riegle GD
Endocrinology; 1985 Apr; 116(4):1316-23. PubMed ID: 3971917
[TBL] [Abstract][Full Text] [Related]
72. A clinical and pharmacodynamic evaluation of sulpiride.
Rao VA; Bailey J; Bishop M; Coppen A
Psychopharmacology (Berl); 1981; 73(1):77-80. PubMed ID: 6785794
[TBL] [Abstract][Full Text] [Related]
73. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
74. Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration.
Möller HJ; Kissling W; Lang C; Doerr P; Pirke KM; von Zerssen D
Am J Psychiatry; 1982 Dec; 139(12):1571-5. PubMed ID: 7149056
[TBL] [Abstract][Full Text] [Related]
75. Multidiagnostic evaluation of prolactin response to haloperidol challenge in schizophrenia: maximal blunting in Kraepelinian patients.
Keks NA; McKenzie DP; Low LH; McGorry PD; Hill C; Kulkarni J; Singh BS; Copolov DL
Biol Psychiatry; 1992 Sep; 32(5):426-37. PubMed ID: 1486148
[TBL] [Abstract][Full Text] [Related]
76. Dosing the antipsychotic medication olanzapine.
Nemeroff CB
J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
[TBL] [Abstract][Full Text] [Related]
77. B-HT 920--a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia.
Wiedemann K; Benkert O; Holsboer F
Pharmacopsychiatry; 1990 Jan; 23(1):50-5. PubMed ID: 1969167
[TBL] [Abstract][Full Text] [Related]
78. A loading-dose strategy for converting from oral to depot haloperidol.
Ereshefsky L; Toney G; Saklad SR; Anderson C; Seidel D
Hosp Community Psychiatry; 1993 Dec; 44(12):1155-61. PubMed ID: 7907570
[TBL] [Abstract][Full Text] [Related]
79. Tardive dyskinesia: clinical and neuroendocrine response to low dose bromocriptine.
Lenox RH; Weaver LA; Saran BM
J Clin Psychopharmacol; 1985 Oct; 5(5):286-92. PubMed ID: 4044881
[TBL] [Abstract][Full Text] [Related]
80. The effect of haloperidol on aldosterone secretion.
Warner MD; Gillespie H; Pavlou SN; Nader S; Peabody CA
Psychoneuroendocrinology; 1992 Oct; 17(5):517-21. PubMed ID: 1484918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
